Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 4/20 | 0.53 |
| ▸ | EGLN1 | Q9GZT9 | 5/20 | 0.40 |
| ▸ | TOP1 | P11387 | 1/20 | 0.39 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.37 |
| ▸ | ACLY | P53396 | 1/20 | 0.35 |
| ▸ | CTSA | P10619 | 1/20 | 0.35 |
| ▸ | KMO | O15229 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3519608 | 0.92 | EGLN3 (0.58) | EGLN3EGLN1TOP1RAB9AMAPK1 | |
| SCHEMBL3520126 | 0.90 | EGLN3 (0.62) | EGLN3EGLN1FTO | |
| SCHEMBL3764754 | 0.89 | LMNA (0.45) | EGLN3TOP1RAB9AMAPK1KDM4E | |
| SCHEMBL3761625 | 0.88 | EGLN3 (0.53) | EGLN3EGLN1TOP1 | |
| SCHEMBL3761128 | 0.87 | EGLN3 (0.55) | EGLN3EGLN1TOP1FTO | |
| SCHEMBL3520229 | 0.86 | EGLN3 (0.49) | EGLN3EGLN1KDM4EFTO | |
| SCHEMBL3763138 | 0.85 | EGLN3 (0.49) | EGLN3EGLN1MAPK1KMO | |
| SCHEMBL3524320 | 0.84 | EGLN3 (0.49) | EGLN3EGLN1RAB9ANPC1 | |
| SCHEMBL3521474 | 0.84 | EGLN3 (0.46) | EGLN3EGLN1FTOKMO | |
| SCHEMBL3519260 | 0.83 | EGLN3 (0.53) | EGLN3EGLN1TOP1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305133-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-12-02 | — | — | US | claimed |
| US-20100305133-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-12-02 | — | — | US | disclosed |
| US-20100305133-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-12-02 | — | — | US | disclosed |
| US-20100305133-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-12-02 | — | — | US | disclosed |
| WO-2009073497-A2 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305133-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | EGLN3 2/4885EGLN1 6/4885TOP1 1959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.